Grifols Sa GRFS
We take great care to ensure that the data presented and summarized in this overview for Grifols SA is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GRFS
View all-
Capital World Investors Los Angeles, CA21MShares$161 Million0.03% of portfolio
-
Brandes Investment Partners, LP La Jolla, CA19.9MShares$153 Million2.11% of portfolio
-
Permian Investment Partners, LP New York, NY12.3MShares$94.7 Million16.06% of portfolio
-
Black Creek Investment Management Inc. Toronto, A611.1MShares$85.3 Million3.5% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny10.7MShares$82.4 Million0.05% of portfolio
-
Armistice Capital, LLC New York, NY9.54MShares$73.2 Million1.41% of portfolio
-
Pictet Asset Management Sa Geneva 73, V86.47MShares$49.7 Million0.07% of portfolio
-
Bank Of America Corp Charlotte, NC5MShares$38.4 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.52MShares$34.7 Million3.41% of portfolio
-
Goldman Sachs Group Inc New York, NY4.51MShares$34.7 Million0.01% of portfolio
Latest Institutional Activity in GRFS
Top Purchases
Top Sells
About GRFS
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum?from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring?to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Insider Transactions at GRFS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|